Insulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progression

Table 1 General characteristics of the 330 patients include in the study

	HBV-HCV group	HBV group	HCV group	P
No. of patients	66	66	198
Medianage (range)	48.5 (25-67)	47 (23-65)	50 (22-65)	NS
Males	60.60%	63.60%	55.50%	NS
Disease duration (yr ± SD)	22.3 ± 9.7	21 ± 7.6	23.2 ± 8.4	NS
BMI (mean ± SD)	25.7 ± 3	26 ± 4.5	26.7 ± 4	NS
Glycaemia (mean ± SD) mg/dL	90 ± 13.4	85.8 ± 14.4a	95 ± 20b	0.09 (a vs b)
HOMA	2.48 ± 2.65c	2.0 ± 1.17	3.63 ± 4.5d	0.042 (c vs d)
Cholesterol (mean ± SD) mg/dL	182 ± 34	182 ± 31	182 ± 41	NS
Triglycerides (mean ± SD) mg/dL	109 ± 55	85 ± 29	103 ± 53	NS
AST (mean ± SD) IU/L	55 ± 39e	83 ± 84f	65 ± 52	0.02 (e vs f)
ALT (mean ± SD), IU/L	44 ± 62.5g	124.95 ± 92h	90 ± 74i	0.001 (g vs h) 0.001 (g vs i) 0.01 (h vs i)
Median HBV DNA (range) IU/mL	1.9 × 103 (1500-10 × 107)	2 × 105 (3000-1× 108)		0.0001
Median HCV RNA (range) IU/mL	1.15 × 105 (120- 6.4 × 105)		6.98 × 105 (2818-8 × 106)	0.025
HCV genotype:
3	7%		8.7%	NS
Non-3	93%		91.3%
HAI score (mean ± SD)	5.9 ± 2.9	6.2 ± 3.4	6.3 ± 3.6	NS
Fibrosis score (mean ± SD)	3.32 ± 0.45l	3.46 ± 0.48m	2.9 ± 0.30n	0.001 (l vs n)
				0.001 (m vs n)

HBV: Hepatitis B virus; HCV: Hepatitis C virus; HOMA: Homeostasis model assessement; AST: Aspartate transferase; ALT: Alanine transferase; NS: No significant.